Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Выбор диуретических лекарственных средств для лечения артериальной гипертензии в амбулаторно-поликлинической практике
Выбор диуретических лекарственных средств для лечения артериальной гипертензии в амбулаторно-поликлинической практике
Морозова Т.Е., Юдина И.Ю. Выбор диуретических лекарственных средств для лечения артериальной гипертензии в амбулаторно-поликлинической практике. Справочник поликлинического врача. 2017; 3: 38–42
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В работе обсуждаются вопросы выбора диуретиков для фармакотерапии артериальной гипертензии, приводится сравнительная характеристика фармакологических свойств тиазидных, тиазидоподобных и петлевых диуретиков. Подробно описаны особенности действия, приводятся обзор доказательной базы петлевого диуретика торасемида и возможности его использования у разных категорий больных артериальной гипертензией.
Ключевые слова: диуретики, тиазидные диуретики, тиазидоподобные диуретики, петлевые диуретики, торасемид, фармакотерапия, артериальная гипертензия.
Key words: diuretics, thiazide diuretics, thiazide-like diuretics, loop diuretics, torasemide, pharmacotherapy, arterial hypertension.
Ключевые слова: диуретики, тиазидные диуретики, тиазидоподобные диуретики, петлевые диуретики, торасемид, фармакотерапия, артериальная гипертензия.
________________________________________________
Key words: diuretics, thiazide diuretics, thiazide-like diuretics, loop diuretics, torasemide, pharmacotherapy, arterial hypertension.
Полный текст
Список литературы
1. 2013 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31 (7): 1281–357.
2. Рекомендации по лечению артериальной гипертонии. ESH/ESC 2013. Рос. кардиол. журн. 2014; 1 (105): 7–94. / Rekomendatsii po lecheniiu arterial'noi gipertonii. ESH/ESC 2013. Ros. kardiol. zhurn. 2014; 1 (105): 7–94. [in Russian]
3. Cooper-Dehoff RM, Gong Y, Handberg EM et al. Tight blood pressure control and cardiovascular outcomes among hypertensives patients with diabetes and coronary artery disease. JAMA 2010; 304: 61–8.
4. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527–35.
5. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
6. Reboldi G, Gentile G, Angeli F et al. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta analysis in patients. J Hypertens 2011; 29: 1253–69
7. Chobanian AV, Bakris GL, Black R et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–52.
8. McCormack T, Krause T, O’Flynn N. Management of hypertension in adults in primary care: NICE guideline. Br J Gen Pract 2012; 62 (596): 163–4.
9. Juaquerto DC, Schini VB, Vanhoutte PM. Indapamide potentiates the endothelium-depend production of cyclic guanosine monophosphate by bradykinine in the canine femoral artery. Am Heart J 1991; 122 (2): 1204–9.
10. Mallion JM, Asmar R, Bouteland S, Guez D. Twenty-four hour antihypertensive efficacy of indapamide 1,5 mg sustained release: results of two randomized double-blind controlled studies. J Cardiovasc Pharmacol 1998; 32 (4): 673–8.
11. Gosse P, Sheridan DJ, Zannad F et al. Regression of left ventricular hypertrophy in hуpertensive patients treated with indapamide SR 1,5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000; 18 (10): 1465–75.
12. Böcker W, Hupf H, Grimm D et al. Effects of indapamide in rats with pressure overload left ventricular hypertrophy. J Cardiovasc Pharmacol 2000; 36 (4): 481–6.
13. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358 (18): 1887–98.
14. Морозова Т.Е. Артериальная гипертония у пожилых: особенности течения и выбор терапии. Consillium Medicum. 2012; 14 (5): 12–6. / Morozova T.E. Arterial'naia gipertoniia u pozhilykh: osobennosti techeniia i vybor terapii. Consillium Medicum. 2012; 14 (5): 12–6. [in Russian]
15. Psaty BM, Lumley T, Furberg CD. Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies. JAMA 2004; 292 (1): 43–4.
16. Dorsch MP, Gillespie BW, Erickson SR et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 2011; 57 (4): 689–94.
17. Asmar R, Amah G, Crisan O, Haddad S. Efficacy and tolerance of indapamide sustained release 1.5 mg on 24-h blood pressure in essential hypertension. Eur Heart J 1999; 1 (Suppl. P): 21–30.
18. Смирнов А.В., Шилов Е.М., Добронравов В.А. и др. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Нефрология. 2012; 16 (1): 89–115. / Smirnov A.V., Shilov E.M., Dobronravov V.A. i dr. Natsional'nye rekomendatsii. Khronicheskaia bolezn' pochek: osnovnye printsipy skrininga, diagnostiki, profilaktiki i podkhody k lecheniiu. Nefrologiia. 2012; 16 (1): 89–115. [in Russian]
19. De la Sierra A, Segura J, Banegas JR et al. Clinical Features of 8295 Patients With Resistant Hypertension Classified on the Basis of Ambulatory Blood Pressure Monitoring. Hypertension 2011; 57: 898–902.
20. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002; 39: 982–8.
21. Brater DC, Leinfelder J, Anderson SA. Clinical pharmacology of torasemide, a new loop diuretic. Clin Pharmacol Ther 1987; 42: 187–92.
22. Masereel B, Ferrari P, Ferrandi M et al. Na+,2Cl–,K+ cotransport system as a marker of antihypertensive activity of new torasemide derivatives. Eur J Pharmacol 1992; 219 (3): 385–94.
23. Spieker C, Zidek W, Hacker W et al. Assessment of intracellular sodium and calcium in essential hypertension during diuretic treatment. Arzneimittelforschung 1988; 38 (1A): 188–90.
24. Yamanaga K, Uchida T, Kido H et al. But not furosemide, increases intracellular cAMP and cGMP content in the aorta of the renal hypertensive rat. J Pharm Pharmacol 1992; 44 (1): 64–5.
25. Roca-Cusachs A, Aracil-Vilar J, Calvo-Gomez C et al. in Hypertension Clinical Trial Investigators Group. Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: A randomized noninferiority trial versus torasemide immediate release. Cardiovasc Ther 2008; 26: 91–100.
26. Гиляревский С.Р., Орлов В.А., Кузьмина И.М., Голшмид М.В. Может ли торасемид пролонгированного действия стать альтернативой тиазидным диуретикам при артериальной гипертонии? Мнение эксперта. Рос. мед. журн. 2012; 20: 1038–43. / Giliarevskii S.R., Orlov V.A., Kuz'mina I.M., Golshmid M.V. Mozhet li torasemid prolongirovannogo deistviia stat' al'ternativoi tiazidnym diuretikam pri arterial'noi gipertonii? Mnenie eksperta. Ros. med. zhurn. 2012; 20: 1038–43. [in Russian]
27. Spannbrucker N, Achhammer I, Metz P, Glocke M. Comparative study on the hypertensive efficacy of torasemide and indapamide in patients with essential hypertension. Drug Res 1988; 38 (1): 190–3.
28. Reyes AJ, Chiesa PD, Santucci MR et al. Hydrochlorothiazide versus a nondiuretic dose of torasemide as once daily antihypertensive monopharmacotherapy in elderly patients; randomized and double-blind study. In: Progress in Pharmacology and Clinical Pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990; p. 183–209.
29. Boelke T, Piesche L. Influence of 2,5–5 mg torasemide o.d. versus 25–50 mg HCTZ/50-100 triamterene o.d. on serum parameters in elderly patients with mild to moderate hypertension. In: Diuretics IV: Chemistry, Pharmacology and clinical Applications. Amsterdam: Excerpta Medica, 1993; p. 279–82.
30. Boelke T, Achhammer I, Meyer-Sabellek WA. Blutdrucksenkung und metabolische Veranderungen bei essentiellen Hypertonikemnach Langzeitgabe unterschiedlicher Diuretika. Hochdruck 1990; 9: 40–1.
31. Baumgart P, Walger P, van Eiff M, Achhammer I. Long-term efficacy and tolerance of torasemide in essential hypertension. In: Krück et al. (Eds). Torasemide: Clinical Pharmacology and Therapeutic Applications. Progress in Pharmacology and Clinical Pharmacology. Vol. 8/1. Stuttgart: Gustav Fischer Verlag, 1990; p. 169–82.
32. Achhammer I, Metz P. Low dose loop diuretics in essential hypertension. Experience with torasemide. Drugs 1991; 41 (Suppl. 3): 80–91.
33. Achhammer I, Eberhard R. Comparison of serum potassium levels during long-term treatment of hypertension patients with 2.5 mg torasemide or 50 mg triamterene/25 mg hydrochlorothiazide o.d. Prog Pharmacol Clin Pharmacol 1990; 8: 211–20.
34. Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther 1993; 7 (Suppl. 1): 63–8.
35. Coca A. Long-term blood pressure control and metabolic disorders induced by torasemide in hypertension. Am J Hypertens 2001; 14: 116A.
36. Ikeda K, Oshima T, Hidaka H, Takasaka T. Molecular and clinical implications of loop diuretic ototoxicity. Hear Res 1997; 107 (1–2): 1–8.
37. Ткачева О.Н., Рунихина Н.К., Шарашкина Н.В. Торасемид: дополнительные преимущества применения при артериальной гипертензии у женщин в постменопаузе. Системные гипертензии. 2013; 10 (2): 9–13. / Tkacheva O.N., Runikhina N.K., Sharashkina N.V. Torasemide: additional benefits for postmenopausal women with arterial hypertension. Systemic Hypertension. 2013; 10 (2): 9–13. [in Russian]
2. Rekomendatsii po lecheniiu arterial'noi gipertonii. ESH/ESC 2013. Ros. kardiol. zhurn. 2014; 1 (105): 7–94. [in Russian]
3. Cooper-Dehoff RM, Gong Y, Handberg EM et al. Tight blood pressure control and cardiovascular outcomes among hypertensives patients with diabetes and coronary artery disease. JAMA 2010; 304: 61–8.
4. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527–35.
5. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
6. Reboldi G, Gentile G, Angeli F et al. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta analysis in patients. J Hypertens 2011; 29: 1253–69
7. Chobanian AV, Bakris GL, Black R et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–52.
8. McCormack T, Krause T, O’Flynn N. Management of hypertension in adults in primary care: NICE guideline. Br J Gen Pract 2012; 62 (596): 163–4.
9. Juaquerto DC, Schini VB, Vanhoutte PM. Indapamide potentiates the endothelium-depend production of cyclic guanosine monophosphate by bradykinine in the canine femoral artery. Am Heart J 1991; 122 (2): 1204–9.
10. Mallion JM, Asmar R, Bouteland S, Guez D. Twenty-four hour antihypertensive efficacy of indapamide 1,5 mg sustained release: results of two randomized double-blind controlled studies. J Cardiovasc Pharmacol 1998; 32 (4): 673–8.
11. Gosse P, Sheridan DJ, Zannad F et al. Regression of left ventricular hypertrophy in hуpertensive patients treated with indapamide SR 1,5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000; 18 (10): 1465–75.
12. Böcker W, Hupf H, Grimm D et al. Effects of indapamide in rats with pressure overload left ventricular hypertrophy. J Cardiovasc Pharmacol 2000; 36 (4): 481–6.
13. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358 (18): 1887–98.
14. Morozova T.E. Arterial'naia gipertoniia u pozhilykh: osobennosti techeniia i vybor terapii. Consillium Medicum. 2012; 14 (5): 12–6. [in Russian]
15. Psaty BM, Lumley T, Furberg CD. Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies. JAMA 2004; 292 (1): 43–4.
16. Dorsch MP, Gillespie BW, Erickson SR et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 2011; 57 (4): 689–94.
17. Asmar R, Amah G, Crisan O, Haddad S. Efficacy and tolerance of indapamide sustained release 1.5 mg on 24-h blood pressure in essential hypertension. Eur Heart J 1999; 1 (Suppl. P): 21–30.
18. Smirnov A.V., Shilov E.M., Dobronravov V.A. i dr. Natsional'nye rekomendatsii. Khronicheskaia bolezn' pochek: osnovnye printsipy skrininga, diagnostiki, profilaktiki i podkhody k lecheniiu. Nefrologiia. 2012; 16 (1): 89–115. [in Russian]
19. De la Sierra A, Segura J, Banegas JR et al. Clinical Features of 8295 Patients With Resistant Hypertension Classified on the Basis of Ambulatory Blood Pressure Monitoring. Hypertension 2011; 57: 898–902.
20. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002; 39: 982–8.
21. Brater DC, Leinfelder J, Anderson SA. Clinical pharmacology of torasemide, a new loop diuretic. Clin Pharmacol Ther 1987; 42: 187–92.
22. Masereel B, Ferrari P, Ferrandi M et al. Na+,2Cl–,K+ cotransport system as a marker of antihypertensive activity of new torasemide derivatives. Eur J Pharmacol 1992; 219 (3): 385–94.
23. Spieker C, Zidek W, Hacker W et al. Assessment of intracellular sodium and calcium in essential hypertension during diuretic treatment. Arzneimittelforschung 1988; 38 (1A): 188–90.
24. Yamanaga K, Uchida T, Kido H et al. But not furosemide, increases intracellular cAMP and cGMP content in the aorta of the renal hypertensive rat. J Pharm Pharmacol 1992; 44 (1): 64–5.
25. Roca-Cusachs A, Aracil-Vilar J, Calvo-Gomez C et al. in Hypertension Clinical Trial Investigators Group. Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: A randomized noninferiority trial versus torasemide immediate release. Cardiovasc Ther 2008; 26: 91–100.
26. Giliarevskii S.R., Orlov V.A., Kuz'mina I.M., Golshmid M.V. Mozhet li torasemid prolongirovannogo deistviia stat' al'ternativoi tiazidnym diuretikam pri arterial'noi gipertonii? Mnenie eksperta. Ros. med. zhurn. 2012; 20: 1038–43. [in Russian]
27. Spannbrucker N, Achhammer I, Metz P, Glocke M. Comparative study on the hypertensive efficacy of torasemide and indapamide in patients with essential hypertension. Drug Res 1988; 38 (1): 190–3.
28. Reyes AJ, Chiesa PD, Santucci MR et al. Hydrochlorothiazide versus a nondiuretic dose of torasemide as once daily antihypertensive monopharmacotherapy in elderly patients; randomized and double-blind study. In: Progress in Pharmacology and Clinical Pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990; p. 183–209.
29. Boelke T, Piesche L. Influence of 2,5–5 mg torasemide o.d. versus 25–50 mg HCTZ/50-100 triamterene o.d. on serum parameters in elderly patients with mild to moderate hypertension. In: Diuretics IV: Chemistry, Pharmacology and clinical Applications. Amsterdam: Excerpta Medica, 1993; p. 279–82.
30. Boelke T, Achhammer I, Meyer-Sabellek WA. Blutdrucksenkung und metabolische Veranderungen bei essentiellen Hypertonikemnach Langzeitgabe unterschiedlicher Diuretika. Hochdruck 1990; 9: 40–1.
31. Baumgart P, Walger P, van Eiff M, Achhammer I. Long-term efficacy and tolerance of torasemide in essential hypertension. In: Krück et al. (Eds). Torasemide: Clinical Pharmacology and Therapeutic Applications. Progress in Pharmacology and Clinical Pharmacology. Vol. 8/1. Stuttgart: Gustav Fischer Verlag, 1990; p. 169–82.
32. Achhammer I, Metz P. Low dose loop diuretics in essential hypertension. Experience with torasemide. Drugs 1991; 41 (Suppl. 3): 80–91.
33. Achhammer I, Eberhard R. Comparison of serum potassium levels during long-term treatment of hypertension patients with 2.5 mg torasemide or 50 mg triamterene/25 mg hydrochlorothiazide o.d. Prog Pharmacol Clin Pharmacol 1990; 8: 211–20.
34. Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther 1993; 7 (Suppl. 1): 63–8.
35. Coca A. Long-term blood pressure control and metabolic disorders induced by torasemide in hypertension. Am J Hypertens 2001; 14: 116A.
36. Ikeda K, Oshima T, Hidaka H, Takasaka T. Molecular and clinical implications of loop diuretic ototoxicity. Hear Res 1997; 107 (1–2): 1–8.
37. Tkacheva O.N., Runikhina N.K., Sharashkina N.V. Torasemide: additional benefits for postmenopausal women with arterial hypertension. Systemic Hypertension. 2013; 10 (2): 9–13. [in Russian]
2. Рекомендации по лечению артериальной гипертонии. ESH/ESC 2013. Рос. кардиол. журн. 2014; 1 (105): 7–94. / Rekomendatsii po lecheniiu arterial'noi gipertonii. ESH/ESC 2013. Ros. kardiol. zhurn. 2014; 1 (105): 7–94. [in Russian]
3. Cooper-Dehoff RM, Gong Y, Handberg EM et al. Tight blood pressure control and cardiovascular outcomes among hypertensives patients with diabetes and coronary artery disease. JAMA 2010; 304: 61–8.
4. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527–35.
5. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
6. Reboldi G, Gentile G, Angeli F et al. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta analysis in patients. J Hypertens 2011; 29: 1253–69
7. Chobanian AV, Bakris GL, Black R et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–52.
8. McCormack T, Krause T, O’Flynn N. Management of hypertension in adults in primary care: NICE guideline. Br J Gen Pract 2012; 62 (596): 163–4.
9. Juaquerto DC, Schini VB, Vanhoutte PM. Indapamide potentiates the endothelium-depend production of cyclic guanosine monophosphate by bradykinine in the canine femoral artery. Am Heart J 1991; 122 (2): 1204–9.
10. Mallion JM, Asmar R, Bouteland S, Guez D. Twenty-four hour antihypertensive efficacy of indapamide 1,5 mg sustained release: results of two randomized double-blind controlled studies. J Cardiovasc Pharmacol 1998; 32 (4): 673–8.
11. Gosse P, Sheridan DJ, Zannad F et al. Regression of left ventricular hypertrophy in hуpertensive patients treated with indapamide SR 1,5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000; 18 (10): 1465–75.
12. Böcker W, Hupf H, Grimm D et al. Effects of indapamide in rats with pressure overload left ventricular hypertrophy. J Cardiovasc Pharmacol 2000; 36 (4): 481–6.
13. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358 (18): 1887–98.
14. Морозова Т.Е. Артериальная гипертония у пожилых: особенности течения и выбор терапии. Consillium Medicum. 2012; 14 (5): 12–6. / Morozova T.E. Arterial'naia gipertoniia u pozhilykh: osobennosti techeniia i vybor terapii. Consillium Medicum. 2012; 14 (5): 12–6. [in Russian]
15. Psaty BM, Lumley T, Furberg CD. Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies. JAMA 2004; 292 (1): 43–4.
16. Dorsch MP, Gillespie BW, Erickson SR et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 2011; 57 (4): 689–94.
17. Asmar R, Amah G, Crisan O, Haddad S. Efficacy and tolerance of indapamide sustained release 1.5 mg on 24-h blood pressure in essential hypertension. Eur Heart J 1999; 1 (Suppl. P): 21–30.
18. Смирнов А.В., Шилов Е.М., Добронравов В.А. и др. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Нефрология. 2012; 16 (1): 89–115. / Smirnov A.V., Shilov E.M., Dobronravov V.A. i dr. Natsional'nye rekomendatsii. Khronicheskaia bolezn' pochek: osnovnye printsipy skrininga, diagnostiki, profilaktiki i podkhody k lecheniiu. Nefrologiia. 2012; 16 (1): 89–115. [in Russian]
19. De la Sierra A, Segura J, Banegas JR et al. Clinical Features of 8295 Patients With Resistant Hypertension Classified on the Basis of Ambulatory Blood Pressure Monitoring. Hypertension 2011; 57: 898–902.
20. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002; 39: 982–8.
21. Brater DC, Leinfelder J, Anderson SA. Clinical pharmacology of torasemide, a new loop diuretic. Clin Pharmacol Ther 1987; 42: 187–92.
22. Masereel B, Ferrari P, Ferrandi M et al. Na+,2Cl–,K+ cotransport system as a marker of antihypertensive activity of new torasemide derivatives. Eur J Pharmacol 1992; 219 (3): 385–94.
23. Spieker C, Zidek W, Hacker W et al. Assessment of intracellular sodium and calcium in essential hypertension during diuretic treatment. Arzneimittelforschung 1988; 38 (1A): 188–90.
24. Yamanaga K, Uchida T, Kido H et al. But not furosemide, increases intracellular cAMP and cGMP content in the aorta of the renal hypertensive rat. J Pharm Pharmacol 1992; 44 (1): 64–5.
25. Roca-Cusachs A, Aracil-Vilar J, Calvo-Gomez C et al. in Hypertension Clinical Trial Investigators Group. Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: A randomized noninferiority trial versus torasemide immediate release. Cardiovasc Ther 2008; 26: 91–100.
26. Гиляревский С.Р., Орлов В.А., Кузьмина И.М., Голшмид М.В. Может ли торасемид пролонгированного действия стать альтернативой тиазидным диуретикам при артериальной гипертонии? Мнение эксперта. Рос. мед. журн. 2012; 20: 1038–43. / Giliarevskii S.R., Orlov V.A., Kuz'mina I.M., Golshmid M.V. Mozhet li torasemid prolongirovannogo deistviia stat' al'ternativoi tiazidnym diuretikam pri arterial'noi gipertonii? Mnenie eksperta. Ros. med. zhurn. 2012; 20: 1038–43. [in Russian]
27. Spannbrucker N, Achhammer I, Metz P, Glocke M. Comparative study on the hypertensive efficacy of torasemide and indapamide in patients with essential hypertension. Drug Res 1988; 38 (1): 190–3.
28. Reyes AJ, Chiesa PD, Santucci MR et al. Hydrochlorothiazide versus a nondiuretic dose of torasemide as once daily antihypertensive monopharmacotherapy in elderly patients; randomized and double-blind study. In: Progress in Pharmacology and Clinical Pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990; p. 183–209.
29. Boelke T, Piesche L. Influence of 2,5–5 mg torasemide o.d. versus 25–50 mg HCTZ/50-100 triamterene o.d. on serum parameters in elderly patients with mild to moderate hypertension. In: Diuretics IV: Chemistry, Pharmacology and clinical Applications. Amsterdam: Excerpta Medica, 1993; p. 279–82.
30. Boelke T, Achhammer I, Meyer-Sabellek WA. Blutdrucksenkung und metabolische Veranderungen bei essentiellen Hypertonikemnach Langzeitgabe unterschiedlicher Diuretika. Hochdruck 1990; 9: 40–1.
31. Baumgart P, Walger P, van Eiff M, Achhammer I. Long-term efficacy and tolerance of torasemide in essential hypertension. In: Krück et al. (Eds). Torasemide: Clinical Pharmacology and Therapeutic Applications. Progress in Pharmacology and Clinical Pharmacology. Vol. 8/1. Stuttgart: Gustav Fischer Verlag, 1990; p. 169–82.
32. Achhammer I, Metz P. Low dose loop diuretics in essential hypertension. Experience with torasemide. Drugs 1991; 41 (Suppl. 3): 80–91.
33. Achhammer I, Eberhard R. Comparison of serum potassium levels during long-term treatment of hypertension patients with 2.5 mg torasemide or 50 mg triamterene/25 mg hydrochlorothiazide o.d. Prog Pharmacol Clin Pharmacol 1990; 8: 211–20.
34. Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther 1993; 7 (Suppl. 1): 63–8.
35. Coca A. Long-term blood pressure control and metabolic disorders induced by torasemide in hypertension. Am J Hypertens 2001; 14: 116A.
36. Ikeda K, Oshima T, Hidaka H, Takasaka T. Molecular and clinical implications of loop diuretic ototoxicity. Hear Res 1997; 107 (1–2): 1–8.
37. Ткачева О.Н., Рунихина Н.К., Шарашкина Н.В. Торасемид: дополнительные преимущества применения при артериальной гипертензии у женщин в постменопаузе. Системные гипертензии. 2013; 10 (2): 9–13. / Tkacheva O.N., Runikhina N.K., Sharashkina N.V. Torasemide: additional benefits for postmenopausal women with arterial hypertension. Systemic Hypertension. 2013; 10 (2): 9–13. [in Russian]
________________________________________________
2. Rekomendatsii po lecheniiu arterial'noi gipertonii. ESH/ESC 2013. Ros. kardiol. zhurn. 2014; 1 (105): 7–94. [in Russian]
3. Cooper-Dehoff RM, Gong Y, Handberg EM et al. Tight blood pressure control and cardiovascular outcomes among hypertensives patients with diabetes and coronary artery disease. JAMA 2010; 304: 61–8.
4. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527–35.
5. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
6. Reboldi G, Gentile G, Angeli F et al. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta analysis in patients. J Hypertens 2011; 29: 1253–69
7. Chobanian AV, Bakris GL, Black R et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–52.
8. McCormack T, Krause T, O’Flynn N. Management of hypertension in adults in primary care: NICE guideline. Br J Gen Pract 2012; 62 (596): 163–4.
9. Juaquerto DC, Schini VB, Vanhoutte PM. Indapamide potentiates the endothelium-depend production of cyclic guanosine monophosphate by bradykinine in the canine femoral artery. Am Heart J 1991; 122 (2): 1204–9.
10. Mallion JM, Asmar R, Bouteland S, Guez D. Twenty-four hour antihypertensive efficacy of indapamide 1,5 mg sustained release: results of two randomized double-blind controlled studies. J Cardiovasc Pharmacol 1998; 32 (4): 673–8.
11. Gosse P, Sheridan DJ, Zannad F et al. Regression of left ventricular hypertrophy in hуpertensive patients treated with indapamide SR 1,5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000; 18 (10): 1465–75.
12. Böcker W, Hupf H, Grimm D et al. Effects of indapamide in rats with pressure overload left ventricular hypertrophy. J Cardiovasc Pharmacol 2000; 36 (4): 481–6.
13. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358 (18): 1887–98.
14. Morozova T.E. Arterial'naia gipertoniia u pozhilykh: osobennosti techeniia i vybor terapii. Consillium Medicum. 2012; 14 (5): 12–6. [in Russian]
15. Psaty BM, Lumley T, Furberg CD. Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies. JAMA 2004; 292 (1): 43–4.
16. Dorsch MP, Gillespie BW, Erickson SR et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 2011; 57 (4): 689–94.
17. Asmar R, Amah G, Crisan O, Haddad S. Efficacy and tolerance of indapamide sustained release 1.5 mg on 24-h blood pressure in essential hypertension. Eur Heart J 1999; 1 (Suppl. P): 21–30.
18. Smirnov A.V., Shilov E.M., Dobronravov V.A. i dr. Natsional'nye rekomendatsii. Khronicheskaia bolezn' pochek: osnovnye printsipy skrininga, diagnostiki, profilaktiki i podkhody k lecheniiu. Nefrologiia. 2012; 16 (1): 89–115. [in Russian]
19. De la Sierra A, Segura J, Banegas JR et al. Clinical Features of 8295 Patients With Resistant Hypertension Classified on the Basis of Ambulatory Blood Pressure Monitoring. Hypertension 2011; 57: 898–902.
20. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002; 39: 982–8.
21. Brater DC, Leinfelder J, Anderson SA. Clinical pharmacology of torasemide, a new loop diuretic. Clin Pharmacol Ther 1987; 42: 187–92.
22. Masereel B, Ferrari P, Ferrandi M et al. Na+,2Cl–,K+ cotransport system as a marker of antihypertensive activity of new torasemide derivatives. Eur J Pharmacol 1992; 219 (3): 385–94.
23. Spieker C, Zidek W, Hacker W et al. Assessment of intracellular sodium and calcium in essential hypertension during diuretic treatment. Arzneimittelforschung 1988; 38 (1A): 188–90.
24. Yamanaga K, Uchida T, Kido H et al. But not furosemide, increases intracellular cAMP and cGMP content in the aorta of the renal hypertensive rat. J Pharm Pharmacol 1992; 44 (1): 64–5.
25. Roca-Cusachs A, Aracil-Vilar J, Calvo-Gomez C et al. in Hypertension Clinical Trial Investigators Group. Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: A randomized noninferiority trial versus torasemide immediate release. Cardiovasc Ther 2008; 26: 91–100.
26. Giliarevskii S.R., Orlov V.A., Kuz'mina I.M., Golshmid M.V. Mozhet li torasemid prolongirovannogo deistviia stat' al'ternativoi tiazidnym diuretikam pri arterial'noi gipertonii? Mnenie eksperta. Ros. med. zhurn. 2012; 20: 1038–43. [in Russian]
27. Spannbrucker N, Achhammer I, Metz P, Glocke M. Comparative study on the hypertensive efficacy of torasemide and indapamide in patients with essential hypertension. Drug Res 1988; 38 (1): 190–3.
28. Reyes AJ, Chiesa PD, Santucci MR et al. Hydrochlorothiazide versus a nondiuretic dose of torasemide as once daily antihypertensive monopharmacotherapy in elderly patients; randomized and double-blind study. In: Progress in Pharmacology and Clinical Pharmacology. Vol. 8. Stuttgart: Gustav Fischer Verlag, 1990; p. 183–209.
29. Boelke T, Piesche L. Influence of 2,5–5 mg torasemide o.d. versus 25–50 mg HCTZ/50-100 triamterene o.d. on serum parameters in elderly patients with mild to moderate hypertension. In: Diuretics IV: Chemistry, Pharmacology and clinical Applications. Amsterdam: Excerpta Medica, 1993; p. 279–82.
30. Boelke T, Achhammer I, Meyer-Sabellek WA. Blutdrucksenkung und metabolische Veranderungen bei essentiellen Hypertonikemnach Langzeitgabe unterschiedlicher Diuretika. Hochdruck 1990; 9: 40–1.
31. Baumgart P, Walger P, van Eiff M, Achhammer I. Long-term efficacy and tolerance of torasemide in essential hypertension. In: Krück et al. (Eds). Torasemide: Clinical Pharmacology and Therapeutic Applications. Progress in Pharmacology and Clinical Pharmacology. Vol. 8/1. Stuttgart: Gustav Fischer Verlag, 1990; p. 169–82.
32. Achhammer I, Metz P. Low dose loop diuretics in essential hypertension. Experience with torasemide. Drugs 1991; 41 (Suppl. 3): 80–91.
33. Achhammer I, Eberhard R. Comparison of serum potassium levels during long-term treatment of hypertension patients with 2.5 mg torasemide or 50 mg triamterene/25 mg hydrochlorothiazide o.d. Prog Pharmacol Clin Pharmacol 1990; 8: 211–20.
34. Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther 1993; 7 (Suppl. 1): 63–8.
35. Coca A. Long-term blood pressure control and metabolic disorders induced by torasemide in hypertension. Am J Hypertens 2001; 14: 116A.
36. Ikeda K, Oshima T, Hidaka H, Takasaka T. Molecular and clinical implications of loop diuretic ototoxicity. Hear Res 1997; 107 (1–2): 1–8.
37. Tkacheva O.N., Runikhina N.K., Sharashkina N.V. Torasemide: additional benefits for postmenopausal women with arterial hypertension. Systemic Hypertension. 2013; 10 (2): 9–13. [in Russian]
Авторы
Т.Е.Морозова*, И.Ю.Юдина
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
*temorozova@gmail.com
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
*temorozova@gmail.com
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
*temorozova@gmail.com
________________________________________________
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
*temorozova@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.